Please ensure Javascript is enabled for purposes of website accessibility

The Best Dividend Aristocrat You Can Buy Right Now

By Keith Speights - Mar 1, 2020 at 9:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And not just because of its dividend.

Dividends are really good. Dividends that keep coming every year are great. But dividends that keep growing year after year are absolutely fantastic.

There's a category of stocks that delivers such fantastic dividends. Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at least 25 consecutive years. Only 57 companies are currently on the list.

Some of these dividend-hiking stocks are better than others. But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (ABT -1.57%).

Hand pointing to a drawing of a light bulb with a dollar sign that is separated from five other light bulbs without dollar signs

Image source: Getty Images.

A rock-solid business

What I like the most about Abbott Labs is that it's simply a great company with a rock-solid business. Abbott ranks as one of the biggest healthcare stocks on the market. It generated $31.9 billion in revenue last year, with a profit of nearly $3.7 billion.

Abbott's medical devices segment rakes in the most money, with sales of more than $12.2 billion in 2019. This unit develops and markets a wide range of products, including cardiac monitors, diabetes-care devices, heart ablation catheters, heart valve clips, neuromodulation devices, and stents.

The company's diagnostics products segment made $7.7 billion in revenue last year. This segment's products include core laboratory testing, molecular diagnostics, point of care diagnostics systems, and rapid diagnostics products for infectious-disease and cardio-metabolic testing.

Trailing close behind is Abbott's nutritional products segment, which generated $7.4 billion in 2019. This business sells nutritional products for children and adults such as Similac and PediaSure.

Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. This unit focuses on marketing drugs to emerging countries including India, Russia, China, and Brazil.

I'm not the only one who thinks Abbott is a great company. Fortune magazine has ranked Abbott among its most admired companies in the world every year since 1984. Abbott has taken the No. 1 spot among medical products companies in Fortune's list in each of the last seven years. Working Mother magazine has listed Abbott in its 100 best companies ranking for 19 consecutive years. And Science magazine has picked Abbott as one of the top employers for 16 years.

Exceptional growth prospects

To be fair, most of the other Dividend Aristocrats also have solid business models. But what I think especially sets Abbott Labs apart from the pack is its exceptionally strong growth prospects. Wall Street analysts project that Abbott will increase its earnings by more than 11% annually over the next five years.

Granted, analysts have higher earnings growth projections for four other Dividend Aristocrats -- Lowe's (LOW -5.26%), ADP (ADP -3.00%), Air Products & Chemicals (APD -2.13%), and Linde (LIN -2.73%). However, I think Abbott's growth is more assured than any of these companies.

All of these other companies depend on a strong economy to achieve their growth. A housing downturn would probably hurt sales for both ADP and Lowe's. A global recession would weaken the financial performance for both of these companies as well as Air Products & Chemicals and Linde. Abbott, on the other hand, should be able to deliver strong earnings growth regardless of what happens at the macroeconomic level.

Just look at some of the key products that should drive Abbott's growth. Freestyle Libre is a continuous glucose monitoring (CGM) system for individuals with diabetes. The Alimta line of diagnostics systems is used for blood and plasma screening and more. MitraClip is a device used to treat mitral regurgitation caused by a leaky heart valve. These devices are going to enjoy strong demand whether the economy is surging or sagging.

A pretty good dividend, too

What about Abbott's dividend? Admittedly, its dividend yield of close to 1.8% isn't as high as the yield of many other Dividend Aristocrats. However, Abbott ranks in the top tier in terms of dividend growth over the last three years and recently boosted its dividend by 12.5%. Abbott also claims one of the more impressive streaks of dividend increases, with 48 consecutive years of dividend hikes. 

Most of the Dividend Aristocrats are relatively good options for income-seeking investors. Abbott is a good pick for growth investors as well. Putting these two positives together along with Abbott's strong position in multiple relatively safe healthcare markets makes this stock the best Dividend Aristocrat around, in my view. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$112.74 (-1.57%) $-1.80
Lowe's Companies, Inc. Stock Quote
Lowe's Companies, Inc.
LOW
$183.82 (-5.26%) $-10.21
Automatic Data Processing, Inc. Stock Quote
Automatic Data Processing, Inc.
ADP
$208.50 (-3.00%) $-6.46
Linde plc Stock Quote
Linde plc
LIN
$310.07 (-2.73%) $-8.70
Air Products and Chemicals, Inc. Stock Quote
Air Products and Chemicals, Inc.
APD
$234.47 (-2.13%) $-5.11
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.43 (-1.52%) $-2.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.